Amiodarone IV Management: Emergency Use, Dosage, Monitoring, and Transition

🩺 Amiodarone IV Management Overview

1. Indication

• Stable or unstable ventricular tachycardia (VT)
• Ventricular fibrillation (VF) unresponsive to defibrillation
• Atrial fibrillation refractory to rate/rhythm control
• Part of ACLS for pulseless VT/VF or wide-complex tachycardia with a pulse

---

2. Standard IV Regimens

ACLS Emergency Protocol:

• Pulseless VT/VF (after CPR and defibrillation):
  • First dose: Amiodarone 300 mg IV push
  • Second dose (if needed): 150 mg IV push
  • Follow with flush (20–30 mL of NS)

With pulse (e.g., stable VT):

• Loading dose: 150 mg in 100 ml D5W over 10 minutes
• Then continuous infusion:
  • 1 mg/min (360 mg over 6 hours)
  • Followed by 0.5 mg/min (720 mg over next 18 hours)

Maintenance Infusion Example:

• 600 mg in 500 ml D5W over 24 hours
  • Approx. 0.42 mg/min: acceptable for post-stabilization infusion
  • Useful when the patient is hemodynamically stable but needs rhythm maintenance

---

3. Duration of IV Amiodarone Use

• Acute phase: 24–48 hours depending on arrhythmia type and response
• Transition: If rhythm is controlled and stable:
  • Switch to oral amiodarone: Start 200 mg BID or 400 mg daily depending on loading need

---

4. Transition to Oral Therapy

• Oral regimen:
  • Loading: 800–1200 mg/day divided doses for 1–2 weeks
  • Maintenance: 200–400 mg/day
• Duration: Long-term therapy for AF or ventricular arrhythmias as needed

---

🧪 Monitoring Protocols During Amiodarone Use

During Infusion (especially IV)

• Continuous cardiac monitoring (ECG)
• Watch for:
  • Bradycardia
  • QT prolongation
  • Hypotension (especially with bolus dosing)

Baseline & Routine Labs:

• Thyroid Function Test (TFT): Risk of hypo-/hyperthyroidism
• Liver Function Test (LFT): Risk of hepatotoxicity
• Pulmonary function test (PFT): Risk of pulmonary fibrosis
• Electrolytes: Hypokalemia or hypomagnesemia increases torsades risk

---

💊 Additional Regimens Summary

---

🔒 Safety Tips (ACLS + Long-Term Use Considerations)

• Always infuse with 5% Dextrose (NOT NS – risk of precipitation)
• Central line preferred for long-term infusion
• Avoid exceeding 24-hour limit in peripheral lines due to phlebitis
• Use in-line filter during infusion
• Stop if signs of:
  • Hypotension
  • Bradyarrhythmia
  • Acute lung toxicity

---

✅ When to Stop IV and Convert to Oral?

Transition after:

• Hemodynamic stability
• Stable rhythm for 24–48 hours
• Completion of loading phase

---

✅ Summary Table